Janssen Korea, Ltd., Korea
janssen.comTotal trials
77
Active
2
Phase 3
3
Total enrollment
39,719
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Esketamine 56 mg | — | — | — | — | — | 1 | |
| Esketamine 84 mg | — | — | — | — | — | 1 |
Next readouts
- 2027-06-25
Top conditions
- Schizophrenia11
- Pain7
- Multiple Myeloma6
- Healthy4
- Epilepsy3
- Chronic Pain3
- Neutropenia3
- Cancer Pain2
Frequently asked questions about Janssen Korea, Ltd., Korea
- How many clinical trials does Janssen Korea, Ltd., Korea have on ClinicalTrials.gov?
- Janssen Korea, Ltd., Korea is listed as the lead sponsor on 77 clinical trials in ClinicalTrials.gov, 2 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Janssen Korea, Ltd., Korea's trials are in Phase 3?
- 3 of Janssen Korea, Ltd., Korea's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does Janssen Korea, Ltd., Korea focus on?
- Janssen Korea, Ltd., Korea's most-studied conditions on ClinicalTrials.gov are Schizophrenia, Pain, Multiple Myeloma, Healthy, Epilepsy.
- When are Janssen Korea, Ltd., Korea's next clinical trial readouts?
- Janssen Korea, Ltd., Korea has 1 upcoming primary-completion readout tracked here; the soonest is “A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression”, expected around 2027-06-25.